Solutions & Small Veins: Optimizing Ablation Results, Optimizing Treatment of Small Vessels Part II, How to Avoid Bad Results & Complications of Sclerotherapy (CONG2011-18)
Steps to Successfully Complete This Activity
To participate in this educational activity please follow the steps listed below.
If you are new to the ACP Online Education Center we require that you register prior to viewing any activity. Click the Register link located in the top right corner of this screen to do so. If you are already a registered user log in and click the TAKE COURSE button that will appear in the Course Summary box.
- To begin the activity click the START COURSE button.
- Progress through course content by using the NEXT button.
- Complete all required items in the course.
- Track your progress using the Course Progress menu.
- On the final page of the activity a link will be provided to download your certificate.
The content of this activity is designed to meet the needs of the following target audience: phlebologists, general surgeons, vascular surgeons, interventional radiologists, interventional cardiologists, vascular medicine practitioners, dermatologists, dermatologic surgeons, family practice and internal medicine practitioners, plastic surgeons, obstetricians and gynecologists, cardiologists, and any other healthcare professional currently or planning on treating patients with venous disease.
As a result of this activity, the participant should be able to identify optimal treatment options for small veins.
- Neil Khilnani, MD, FACPh, discloses that he is the Data Safety Monitor for Sapheon. He also discloses off label use of the following drugs: Hypertonic Saline, Hypertonic Dextrose, Glycerin, Dilution of Sodium tetradecyl sulfate and Polidocanol. The use of drugs for Sclerotherapy has not been approved by the Federal Drug Administration (FDA).
- Julie Karen, MD, has nothing to disclose.
- Jean-Jerome Guex, MD, FACPh discloses that he is a Shareholder and SAC Member; Investigator and Speaker for Vascular Insights, InnoTech, Servier, Pierre Fabre, Sigvaris, and Kreussler. He provides disclosure of the following non-FDA approved drugs: Polidocanol foam, as referred to in this talk, has not been approved for use by the Federal Drug Administration(FDA). Polidocanol concentrations >1% are not registered in the USA. Sclerodex is not registered in the USA. Chromated Glycerin (Sclermo) is also not registered in the USA.
The views and opinions expressed in this activity are those of the faculty and do not necessarily represent the views of the ACP. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting professional use of any of the information provided herein. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of ACP Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Discussion of Off-Label Use
Although no longer required by the Accreditation Council for Continuing Medical Education (ACCME), ACP CME requests all faculty to inform learners of any products they will discuss that are off-label or investigational.
Reproduction of this material is not permitted without written permission from the copyright owner.